Clinical trials: Non Alcoholic Fatty Liver
Fibrosis, Inflammation
A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of RXC007.
- Conditions
- Fibrosis, Inflammation, Idiopathic Pulmonary Fibrosis, Non-alcoholic Steatohepatitis
- Trial name
- NCT04931147
- Testing
- RXC007
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Redx Pharma Ltd
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver
European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD)
The EU-PNAFLD (The European Paediatric NALFD Registry) will be a network composed of European centres involved in the care of children with NAFLD, and will include Hepatologists, Endocrinologists, and Scientists, supported by…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver, Non-alcoholic Steatohepatitis
- Trial name
- EU-PNAFLD (NCT04190849)
- Where
- 3 sites in Netherlands, United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease
Liver Stiffness And Steatosis Assessment In Women With Polycystic Ovary Syndrome Using Fibroscan
Polycystic Ovary Syndrome (PCOS) is a complex endocrine and metabolic disorder prevalent among women of reproductive age. It is closely associated with insulin resistance, obesity, and metabolic dysfunction, often leading to…
- Trial name
- NCT07027332
- Testing
- FibroScan® (Echosens, Paris, France)
- Where
- Turkey (Türkiye)
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Bezmialem Vakif University
Metabolic Dysfunction-associated Steatotic Liver Disease, Hepatic Steatosis
Hyperbaric Oxygen Therapy for Metabolic Dysfunction-associated Steatotic Liver Diseases
The goal of this clinical trial is to learn if hyperbaric oxygen therapy (HBOT) works to treat Metabolic Dysfunction-associated Steatotic Liver Diseases (MASLD).
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease, Hepatic Steatosis, Non-alcoholic Fatty Liver Diseases
- Trial name
- MASLD (NCT06619808)
- Testing
- Hyperbaric oxygen therapy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Jinling Hospital, China
NAFLD, NASH - Nonalcoholic Steatohepatitis
Nonalcoholic Fatty Liver Disease in HIV Database
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions associated with fat accumulation that ranges from benign, non-progressive liver fat accumulation to severe liver injury, cirrhosis, and liver failure.
- Conditions
- NAFLD, NASH - Nonalcoholic Steatohepatitis, Hiv
- Trial name
- NCT05023044
- Where
- 8 sites in United States
- Volunteers
- 400 people
- Sponsor
- Johns Hopkins University
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease
To investigate the efficacy and safety of 4 mg/day of WY-8678 (guanabenz acetate) and 8 mg/day of WY-8678 (guanabenz acetate) in patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH patients)…
- Trial name
- NCT05084404
- Testing
- Experimental: 4 mg/day of WY-8678 (guanabenz acetate), Experimental: 8 mg/day of WY-8678 (guanabenz acetate)
- Where
- Japan
- Volunteers
- 29 people
- Sponsor
- Yokohama City University
Simple Steatosis Non Fatty Liver
N-acetyl Cysteine and Patients with Non-alcoholic Fatty Liver Disease
Effect of N-acetyl cysteine on markers of oxidative stress and insulin resistance in patients with Non-alcoholic fatty liver disease
- Trial name
- NCT05589584
- Testing
- N acetyl cysteine with weight reduction
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Hepatitis C, Non-Alcoholic Fatty Liver Disease
Phase I Trial of Silymarin for Chronic Liver Diseases
The purpose of this study is to determine the safety and tolerability of different dosages of silymarin on subjects with Hepatitis C or Non-Alcoholic Fatty Liver Disease.
- Trial name
- SyNCH (NCT00389376)
- Testing
- Silymarin
- Where
- 5 sites in United States
- Volunteers
- 56 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Non-alcoholic Fatty Liver Disease, Chronic Kidney Disease
Genetical Background of Non-alcoholic Fatty Liver Disease (NAFLD) in Diabetes Mellitus and in Chronic Kidney Disease
The present study investigates relationship between non-alcoholic fatty liver disease and its risk factors, such as genetic background and diseases, such as chronic kidney disease and diabetes mellitus.
- Conditions
- Non-alcoholic Fatty Liver Disease, Chronic Kidney Disease, Diabetes Mellitus
- Trial name
- NAFLDDMCKD (NCT02947568)
- Testing
- non-interventional study
- Where
- Hungary
- Volunteers
- 600 people
- Sponsor
- University of Pecs
Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease
Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes Subjects
This study is conducted to test the hypothesis that in uncontrolled type 2 diabetic adults treatment with diacerein will improve glycemic control and will reduce liver fat within a 24 month period.
- Trial name
- DGCLFT2DM (NCT02242149)
- Testing
- Diacerein
- Where
- Brazil
- Volunteers
- 84 people
- Sponsor
- Universidade Federal do Rio de Janeiro
NAFLD
NAFLD in Diabetes Type 2 in Primary Care
The EPSONIP (Evaluating Prevalence and Severity Of NAFLD In Primary care) trial is a longitudinal cohort study of patients with T2DM recruited from primary health care centers in Östergötland, Sweden.
- Trial name
- EPSONIP (NCT03864510)
- Where
- 2 sites in Sweden
- Volunteers
- 317 people
- Sponsor
- Linkoeping University
Insulin Resistance, Nonalcoholic Fatty Liver Disease
Insulin Resistance in Nonalcoholic Fatty Liver Disease: A Case Control Study
We hypothesize that insulin resistance is characteristic of nonalcoholic fatty liver disease as compared to age, gender, non-diabetic BMI-matched control subjects, both healthy and those with non-cirrhotic, non-steatotic liver…
- Trial name
- NCT00637520
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Duke University
Non-Alcoholic Fatty Liver Disease
Motivational Interviewing in the Management of Non Alcoholic Fatty Liver Disease
The goal of this study is to assess if motivational counselling works to reduce the weight in participants with Non Alcoholic Fatty Liver Disease (NAFLD).
- Trial name
- NCT06348628
- Testing
- Motivational Interview
- Where
- Sri Lanka
- Volunteers
- 231 people
- Sponsor
- Madunil Anuk Niriella
Metabolic Dysfunction-associated Steatotic Liver Disease
Digital Pathology and AI for Liver Outcomes in MASLD
The aim of this multi-center, retrospective epidemiologic study is to confirm the prognostic performance of the Digital Pathology (DP) FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS), derived from standard digital…
- Trial name
- DPAILO-1 (NCT06344364)
- Testing
- Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)
- Where
- 3 sites in Hong Kong, Spain
- Volunteers
- 1,241 people
- Sponsor
- PharmaNest, Inc
Non-Alcoholic Fatty Liver Disease
Gemcabene for the Treatment of Pediatric NAFLD
This is a multicenter, prospective, open-label, Phase 2, proof of concept study to test preliminary efficacy and safety of gemcabene in children with established nonalcoholic fatty liver disease (NAFLD) incompletely treated by…
- Trial name
- NCT03436420
- Testing
- Gemcabene
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Emory University
Non Alcoholic Steatohepatitis
Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis
The purpose of the study is to see if the drug ezetimibe is a potential treatment for Nonalcoholic Steatohepatitis(NASH).
- Trial name
- NCT01766713
- Testing
- Ezetimibe
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Fatty Liver Disease
Synbiotics Impact on Insulin and TNF-α in MAFLD: a Gut Microbiota Profile Analysis
Primary Objective: To analyze the effect of synbiotic supplementation on metabolic profile, insulin and TNF-α and gut microbiota changes in patients with Metabolic dysfunction-Associated Fatty Liver Disease (MAFLD).
- Trial name
- NCT06585982
- Testing
- Treatment, Control
- Where
- Indonesia
- Volunteers
- 50 people
- Sponsor
- Universitas Diponegoro
Non-Alcoholic Steatohepatitis (NASH)
Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH)
Double-blind, randomized, placebo-controlled study to explore the safety, tolerability PK characteristics and early efficacy of ZSP1601 tablets in patients with non-alcoholic steatohepatitis (NASH).
- Trial name
- NCT04140123
- Testing
- ZSP1601
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Conditionally Increased Output (CIO) Enhanced Ultrasound System
This study aims to assess possible bioeffects that may be caused by the use of shear wave elastography (SWE) with conditionally increased acoustic output pressure (CIO).
- Conditions
- Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Fatty Liver
- Trial name
- NCT05792423
- Testing
- GE ultrasound system with increased acoustic output settings
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Non-Alcoholic Fatty Liver Disease
Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan
The goal of this study is to evaluate the role of probiotics in the treatment of pediatric NAFLD by evaluating for steatosis and fibrosis with a Fibroscan machine.
- Trial name
- NCT04671186
- Testing
- Culturelle (Lactobacillus rhamnosus strain GG)
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Northwell Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.